Allison Betof Warner, MD, PhD
@DrBetofMDPhD
Director of Melanoma Program, Director of Solid Tumor Cell Therapy @StanfordCancer | wife/dog mom🐾/CF-L2 | FCOI: https://t.co/BQzZa9DdO7…
ID:721788669749698560
https://profiles.stanford.edu/allison-betof-warner 17-04-2016 19:53:23
7,1K Tweets
4,6K Followers
2,3K Following
🚨 Allison Betof Warner, MD, PhD (@StanfordCancer) asks if we’ve reached the tip of the iceberg with TIL therapy for #Melanoma at #iwCART 24 . Join the conversation on cutting-edge treatments!
#iwCART 24 VJ Oncology #iwCART #CART #CellularTherapies
SCI members @adamdelazerd, Yonatan Winetraub, Kavita Sarin, & others developed a noninvasive #VirtualBiopsy using micro-registered optical coherence tomography. bit.ly/3xA0JSb
SCI leader Mackall Lab & others found that a protein called #FOXO1 improves the survival and function of CAR T cells, which may lead to more effective #CARTcell therapies &could potentially expand its use in difficult-to-treat cancers. go.nature.com/43UJBCs #CellTherapy
New #JITC position article and guidelines: Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy bit.ly/3PZVxNM Steven Chen 陳持威, MD, MPH, MHPEd Eugene Semenov, MD Allison Betof Warner, MD, PhD Jarushka Naidoo Kerry Reynolds
Ongoing ph1 trial of systemically administered IL13RA2 CAR T cells. Who to screen for target expression?
- melanoma if considering TIL (Melanoma Research)
- pheo/para (@pheopara)
- neuroendocrine tumors (@LACNETS)
- adrenocortical carcinoma
- thyroid cancers
- sarcoma (MPNST/UPS)
🚨Fantastic pair of papers in nature today from Evan Weber, Mackall Lab and the Darcy lab Peter Mac Cancer Centre on enforcing stem-like molecular programs in therapeutic T cells through overexpression of #FOXO1 ! 👇
nature.com/articles/s4158…. Children's Hospital Stanford Cancer Institute Parker Institute for Cancer Immunotherapy
Wonderful talk by Allison Betof Warner, MD, PhD of Stanford Medicine on the “Tip of the Iceberg” that recent approval of lifileucel (the first approved #TIL therapy) reflects for melanoma therapy. Her group infused the world’s 1st commercial patient yesterday! #immunotherapy
Allison Betof Warner, MD, PhD highlighting work by Adam J. Schoenfeld at Memorial Sloan Kettering Cancer Center showing early potential for experimental #TIL therapy for NSC #lungcancer .
Early days—lots of opportunity to improve strategies to better approach results of #tcellrx in blood cancers.
Allison Betof Warner, MD, PhD highlighting future strategies including Obsidian’s engineering of TILs with acrtazolamide-modified membrane bound IL-15 signaling that might obviate need for toxic IL-2 therapy following TIL infusion in #melanoma and other cancers. #immunotherapy
Incredibly proud of our Melanoma and Cell Therapy teams at Stanford Cancer Institute. We performed the first commercial lifileucel (AMTAGVI) infusion this afternoon. We are so excited to bring this treatment for advanced melanoma to our patients! #CellTherapy #TIL (posted with consent)
Society for Immunotherapy of Cancer ACCC Expanding Access to Cellular and Bispecific Therapies Workshop
great experience with Jason Luke, MD, FACP Allison Betof Warner, MD, PhD Sigrun Hallmeyer and team. important with the approval of TIL
with gabriela iovance Amtagvi
sitcancer.org/viewdocument/s…
Just received & share here a reminder to join the #ISEO planning meeting American College of Sports Medicine Annual Meeting pre conf (May/28th, #Boston )
✅To all interested in #ExerciseOncology
See you there!!
Dr Kathryn Schmitz
Allison Betof Warner, MD, PhD
Anne May
Kristin Campbell, PhD
👉 acsm.informz.net/informzdataser…
